Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-blind Study of Bifeprunox vs Quetiapine in Schizophrenia
2006-004973-83Phase 3Terminated
- Sponsor
- Solvay Pharmaceuticals
- Start
- Apr 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bifeprunox in schizophrenia (2 arms), sponsored by Solvay Pharmaceuticals. Primary endpoint: Change in body weight over 8 weeks. Started Apr 2007; status: terminated.
02
Drugs
bifeprunox
03
Conditions
schizophrenia
Beyond the preview
Go deeper on 2006-004973-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004973-83.